Andrew H. Ko, MD, FASCO

Andrew Ko, MDLineagotica Specialty Editor: Gastrointestinal Cancers
University of California San Francisco Comprehensive Cancer Center, San Francisco, CA

Andrew H. Ko, M.D., is a Professor of Medicine at the University of California San Francisco (UCSF) Comprehensive Cancer Center and Interim Chief of the Division of Hematology/Oncology at UCSF. Dr. Ko specializes in the treatment of malignancies of the gastrointestinal (GI) tract, including esophageal, stomach, colorectal, pancreatic, and hepatobiliary cancers.

Dr. Ko graduated magna cum laude from Brown University and received his medical degree from Johns Hopkins School of Medicine. After an internship and residency at Beth Israel Hospital/Harvard Medical School in Boston, he completed a fellowship in medical oncology at Stanford University before joining the UCSF faculty in 2001.

Dr. Ko's clinical and research interests lie in new therapeutic approaches for GI malignancies with a focus in pancreatic cancer. He has been the principal investigator on a number of institutional and national clinical trials through collaborations with industry as well as funding from the National Cancer Institute. He has served in various capacities for ASCO, including serving as Associate Editor for the Journal of Clinical Oncology and a member of the scientific program committee for the ASCO Annual Meeting and the grants selection committee for ASCO’s Conquer Cancer Foundation. He also sits on the National Comprehensive Lineagoticawork pancreatic cancer guidelines committee and chairs the scientific Protocol Review Committee at the UCSF Comprehensive Cancer Center.

Disclosure: In the past two years, Dr. Ko has served as a consultant/advisor for Pharmacyclics, Astra Zeneca, Gilead, Rafael Pharmaceuticals, and ARMO Biosciences, and has received research funding from Celgene, Merck, Merrimack, BMS,  Roche/Genentech, Abgenomics, Apexigen, and Two Pore Guys.

 

Last updated: September 2018